Evidence map›Paper›PMID 40304150›Full record

ArticleACS infectious diseases2025

Cryo-EM Structure of HIV-1 Reverse Transcriptase with

Megan A Young, Thomas R Lane, Renuka Raman, Julie A E Nelson, Olga Riabova, Elena Kazakova, Natalia Monakhova, Andrey Tsedilin, Steven D Rees, Daniel Quinnell and 3 more

Abstract read
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Megan A YoungSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, San Diego, California 92093, United States.
Thomas R LaneCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab, 3510, Raleigh, North Carolina 27606, United States.ORCID 0000-0001-9240-4763
Renuka RamanCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab, 3510, Raleigh, North Carolina 27606, United States.
Julie A E NelsonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina 27514, United States.
Olga RiabovaResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, Moscow 119071, Russia.
Elena KazakovaResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, Moscow 119071, Russia.
Natalia MonakhovaResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, Moscow 119071, Russia.
Andrey TsedilinResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, Moscow 119071, Russia.
Steven D ReesSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, San Diego, California 92093, United States.ORCID 0000-0002-2258-7469
Daniel QuinnellSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, San Diego, California 92093, United States.
Vadim MakarovResearch Center of Biotechnology RAS, Leninsky Prospekt 33-2, Moscow 119071, Russia.ORCID 0000-0001-8746-2694
Geoffrey ChangSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, San Diego, California 92093, United States.
Sean EkinsCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab, 3510, Raleigh, North Carolina 27606, United States.ORCID 0000-0002-5691-5790

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Centralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3M
New generation of non-nucleoside RT HIV inhibitors avoiding HIV-associated neurocognitive disordersR01NS102164 · NINDS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN, NELSON, JULIE AE · 2017 to 2019
$587k
MegaTox for analyzing and visualizing data across different screening systemsR43ES031038 · NIEHS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2019 to 2020
$349k
NIAID NIH HHS P30 AI050410NIEHS NIH HHS R43 ES031038NIGMS NIH HHS R44 GM122196NINDS NIH HHS R01 NS102164
6 · The paper itself

Abstract

The use of highly active antiretroviral therapy (HAART) has made the human immunodeficiency virus (HIV) a chronic disease rather than a terminal disease. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of HAART, although we are seeing clinically relevant drug-resistant mutants such that there is a need to develop new molecules. We recently identified a new class of

Indexed as

Anti-HIV AgentsHIV-1HIV Reverse TranscriptaseReverse Transcriptase InhibitorsTriazolesCryoelectron MicroscopyHumansModels, MolecularAnti-HIV AgentsHIV Reverse Transcriptasereverse transcriptase, Human immunodeficiency virus 1Reverse Transcriptase InhibitorsTriazolescryo-EMdrug-resistant mutanthighly active antiretroviral therapyhuman immunodeficiency virusnon-nucleoside reverse transcriptase inhibitors

Identifiers

PMID40304150
PMCPMC12150279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.